Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 12c
July 27, 2016 4:42 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.11), $0.12 better than the analyst estimate of ($0.23).
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
... More